Valore202020212022202320242025TTMSpese di vendita, generali e amministrative11.29 B15.23 B18.42 B19.22 B19.98 B19.93 B—Ricerca e sviluppo5.99 B9.74 B9.76 B10.94 B13.58 B14.23 B—Reddito operativo5.16 B1.06 B3.76 B8.19 B10 B13.74 B—Proventi non operativi, Totale———————Oneri finanziari, al netto degli interessi capitalizzati———————Proventi non operativi, esclusi gli oneri finanziari———————Entrate/uscite straordinarie———————Utile al lordo delle imposte3.92 B265 M2.5 B6.9 B8.69 B12.4 B—Quota di utile———————Imposte772 M380 M792 M938 M1.65 B2.17 B—Interessi di minoranza52 M3 M5 M6 M6 M8 M—Altri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate3.14 B115 M3.29 B5.96 B7.04 B10.23 B—Attività cessate———————Utile netto3.14 B115 M3.29 B5.96 B7.04 B10.23 B—Regolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari———————Utile base per azione (EPS base)———————Utile diluito per azione (EPS diluito)———————Numero medio di azioni ordinarie in circolazione———————Azioni diluite in circolazione———————EBITDA———————EBIT———————Costo del fatturato5.3 B12.44 B12.39 B8.27 B10.21 B10.63 B—Altri costi del venduto———————Ammortamento e svalutazione (liquidità)———————
AstraZeneca PLC - American Depositary Shares
AstraZeneca plc is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje.